Chronic Hepatitis C in Saudi Arabia: Three Years Local Experience in a University Hospital

Author(s):
Hisham O AkbarHisham O Akbar1,*, Ahmad Al GhamdiAhmad Al Ghamdi2, Faten QattanFaten Qattan2, Hind I FallatahHind I Fallatah1, Maha Al RumaniMaha Al Rumani2
1Department of Internal Medicine, King Abdul Aziz University Hospital, gihepa@yahoo.com, Saudi Arabia
2Molecular Biology Department, King Abdul Aziz University Hospital, Saudi Arabia

Hepatitis Monthly:Vol. 12, issue 9; 6178
Published online:Sep 30, 2012
Article type:Research Article
Received:May 23, 2012
Accepted:Jul 28, 2012
How to Cite:Akbar H O, Al Ghamdi A, Qattan F, Fallatah H I, Al Rumani M. Chronic Hepatitis C in Saudi Arabia: Three Years Local Experience in a University Hospital.Hepat Mon.2012;12(9):6178.https://doi.org/10.5812/hepatmon.6178.

Abstract

Background:

Chronic hepatitis C (CHC) is a global infection. In Saudi Arabia, the prevalence of CHC is declining due to the implementation of a blood screening program. However, CHC still remains a leading cause of liver cirrhosis and hepatocellular carcinoma.

Objectives:

This is a retrospective study of CHC patients at the King Abdul Aziz University Hospital, Jeddah, Saudi Arabia.

Patients and Methods:

Out of a total of 291 CHC patients from the hepatology clinic at King Abdul Aziz University hospital, Jeddah, 279 patients were included in the present study. They were primarily male (152, 54.5%), with a mean age of 50.41 1.72 years. The majority of patients were either Saudi (108, 38.7%) or Egyptian (60, 21.5%). A total of 61 patients received combination treatment with pegylated interferon and ribavirin, and one patient with sickle-cell anemia received pegylated INF monotherapy. Demographic, clinical and laboratory features of the CHC patients, and their responses to treatment were studied.

Results:

Decompensated cirrhosis was documented in 60 patients (21.5%), and hepatocellular carcinoma in 14 (5%). The mean level of serum alanine aminotransferase was 83.6 231 u/L. The predominant genotype among the 70 patients tested, was genotype 4, followed by genotype 1 (39 and 18 patients, respectively). The sustained viral response (SVR) rate was 82.99%. The main predictive factors for SVR were baseline HCV viral load and rapid virologic response (RVR). The mean duration of follow-up was 4.2 .85 years. There were 24 patients who had liver disease-related mortality.

Conclusions:

our data showed that 22% of CHC patients progress to cirrhosis and another 22% had treatment. Liver related mortality was more common in patients with advanced cirrhosis.

Full Text

Full text is available in PDF


Crossmark
Crossmark
Checking
Share on
Cited by
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles